Qiagen N.V. (QGEN)

Qiagen NV (NASDAQ:QGEN) is ranked as a Hold using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Currently, Qiagen NV (NASDAQ:QGEN) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing system. QGEN has recently seen its Portfolio Grader rating downgraded over the last month from a Buy to a Hold.

Currently, Qiagen NV (NASDAQ:QGEN) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. QGEN has recently seen its Portfolio Grader rating downgraded over the last month from a Buy to a Hold.

With a $7.2 billion market value, Qiagen NV (NASDAQ:QGEN) ranks in the top half of its industry group, Life Sciences Tools & Services, and in the top 25% of its sector group, Health Care, in market value. From the prospective of investment attractiveness, The current Portfolio Grader ranking for QGEN puts it 23 among the 33 companies in this industry group, giving it a below-average spot; in the third quartile of the sector with a ranking of 453 among the 782 companies in the sector, and number 2,909 in the nearly 5,000 company Portfolio Grader universe.

Qiagen NV (NASDAQ:QGEN) is one of 33 companies within the Life Sciences Tools & Services GICS industry group, which is in turn part of the 785 company GICS Health Care sector. QGEN has a market value of $7.7 billion which is in the top half of its industry group. The ranking for QGEN by Portfolio Grader places it 21 among the 33 companies in this industry group, giving it a lower than average position; in the top half of the sector with a ranking of 338 among the 785 companies in the sector, and number 2,179 in the nearly 5,000 company Portfolio Grader universe.

Qiagen NV (NASDAQ:QGEN) is ranked as a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. QGEN has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.

Portfolio Grader currently ranks Qiagen NV (NASDAQ:QGEN) a Buy. The methodology for investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. QGEN has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.

Qiagen NV (NASDAQ:QGEN) is a component of the 33 company Life Sciences Tools & Services GICS industry group, which is a segment of the 783 company GICS Health Care sector. The market value of QGEN is $7.9 billion which falls in the top quarter of its industry group. Portfolio Grader's current ranking for QGEN puts it 13 among the 33 companies in this industry group, giving it an above-average position; in the top quartile of the sector with a ranking of 175 among the 783 companies in the sector, and number 1,279 in the nearly 5,000 company Portfolio Grader universe.

Currently, Qiagen NV (NASDAQ:QGEN) has a Hold using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. QGEN has maintained this ranking for the last month.

Currently, Qiagen NV (NASDAQ:QGEN) has a Hold using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. QGEN has maintained this ranking for the last month.